Latest Utilities News

Piedmont Lithium reported a 15% decline in Q1 2025 spodumene concentrate production due to weather disruptions, yet achieved a record lithium recovery rate in March, signaling operational resilience amid challenges.

Cauldron Energy reports a maiden inferred uranium resource of 11.1 million pounds at Manyingee South, boosting total Yanrey Project resources by 35%. The company also expands its footprint with six new tenements, positioning itself strongly amid a bullish uranium market.

Revolver Resources has completed the SX-EW FEED for its Dianne Copper Mine Project, marking a key technical milestone and progressing towards a Final Investment Decision. The company also secured A$1.5 million through non-dilutive royalties, underpinning its funding strategy.

Radiopharm Theranostics has bolstered its cash position with an $8 million placement from Lantheus Holdings, now its largest shareholder. New clinical data highlight promising advances in brain metastases detection and HER2-targeted radiopharmaceutical therapies.

Anson Resources has applied to re-enter the Mt Fuel-Skyline Geyser 1-25 well at its Green River Lithium Project to test for lithium-rich brines, aiming to upgrade its exploration target to a JORC Mineral Resource.

TPC Consolidated Limited has extended the sunset date of its acquisition scheme with Wollar Solar Holding to June 30, 2025, as it awaits Foreign Investment Review Board approval. The extension underscores regulatory hurdles impacting the transaction timeline.

Altamin Limited reports steady progress on its Lazio and Gorno projects, with positive testwork confirming the feasibility of sulphate of potash, lithium carbonate, and boron recovery from geothermal brines. The company moves closer to pre-feasibility studies and environmental approvals amid a tight cash position.

ikeGPS delivered a robust 4Q25 with a 48% jump in annual subscription revenue exit run rate and secured major U.S. utility contracts, while declining a $170 million acquisition offer due to shareholder resistance.

Race Oncology has opened a second Australian clinical site for its Phase 1 trial of RC220 combined with doxorubicin in advanced solid tumours, aiming to speed patient enrolment and gather critical safety and efficacy data.

ikeGPS delivered a robust 4Q FY25 with a 48% jump in annual subscription revenue and closed NZ$12 million in contracts, while receiving a non-binding acquisition approach valuing the company at around NZ$165-170 million.

ikeGPS Group Limited reported a robust 48% increase in annual subscription revenue exit run rate for FY25, driven by major U.S. utility contracts, while declining a non-binding $170 million acquisition offer due to shareholder resistance.

Atturra Limited reports a robust first half of FY25 with revenue growth nearing 28%, driven by recent acquisitions and expanding service offerings, while updating full-year guidance amid cautious government sector risks.